MARKET

AXSM

AXSM

Axsome Therapeut
NASDAQ
84.73
+2.59
+3.15%
Opening 11:44 07/19 EDT
OPEN
82.63
PREV CLOSE
82.14
HIGH
85.12
LOW
82.07
VOLUME
166.51K
TURNOVER
0
52 WEEK HIGH
98.40
52 WEEK LOW
55.02
MARKET CAP
4.02B
P/E (TTM)
-13.2725
1D
5D
1M
3M
1Y
5Y
1D
Decoding 9 Analyst Evaluations For Axsome Therapeutics
Axsome Therapeutics has been analyzed by 9 analysts in the last three months. The company is a clinical-stage biopharmaceutical company developing novel therapies for the management of the central nervous system. The analysts have set 12-month price targets of $129.89 and $190.00 for the company. The average price target has increased by 2.19% in the past month.
Benzinga · 1d ago
Axsome Therapeutics Price Target Cut to $95.00/Share From $97.00 by B of A Securities
Dow Jones · 1d ago
Axsome Therapeutics Is Maintained at Neutral by B of A Securities
Dow Jones · 1d ago
B of A Securities Maintains Neutral on Axsome Therapeutics, Lowers Price Target to $95
Benzinga · 1d ago
Wall Street Analysts Predict a 49.36% Upside in Axsome (AXSM): Here's What You Should Know
NASDAQ · 1d ago
AXSOME THERAPEUTICS INC <AXSM.O>: BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $95 FROM $97
Reuters · 1d ago
Axsome Therapeutics: Stable Auvelity Growth and Coverage Amid New GPO Contract
TipRanks · 2d ago
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
NASDAQ · 2d ago
More
About AXSM
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Webull offers Axsome Therapeutics Inc stock information, including NASDAQ: AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.